5-fluoro-1-benzothiophene-3-carbaldehyde | 40740-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 5-fluoro-1-benzothiophene-3-carbaldehyde
• 英文别名: 5-fluorobenzo[b]thiophene-3-carbaldehyde；5-Fluorbenzothiophen-3-carboxaldehyd；5-Fluoro-benzo[b]thiophene-3-carbaldehyde
• CAS: 40740-56-5
• 化学式: C₉H₅FOS
• 分子量: 180.203
• InChiKey: FGNHFMZSRGUTMC-UHFFFAOYSA-N

物化性质

• 沸点：
  307.0±22.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-fluoro-1-benzothiophene-3-carbaldehyde 、 4-(4-氨基丁1-基)氨基喹啉 在 溶剂黄146 、 sodium tetrahydroborate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 14.0h， 以59%的产率得到N-[(5-fluoro-1-benzothiophen-3-yl)methyl]-N'-(quinolin-4-yl)butane-1,4-diamine
  参考文献：
  名称：

  以苯并噻吩部分为氨基喹啉伴侣的抗疟药。

  摘要：

  疟疾是由疟原虫寄生虫引起的一种严重且危及生命的疾病，该寄生虫通过被感染的按蚊叮咬传播到人类。在这里，我们报告氨基喹啉偶联苯并噻吩和噻吩环在抑制恶性疟原虫寄生虫生长中的功效。评价合成的化合物在体外和小鼠中的抗疟活性和毒性。本文介绍的苯并噻吩在以160 mg / kg /天×3天的口服剂量给药后，对氯喹敏感（CQS）菌株的活性增强，IC50 = 6 nM，治愈了5/5感染了伯氏疟原虫的小鼠。在苯并噻吩系列中，所检测的抗疟原虫抗CQS菌株D6的活性高于抗氯喹（CQR）W2和耐多药性（MDR）TM91C235的菌株。对于噻吩系列，发现了一个非常有趣的功能：对CQR菌株过敏，抗性指数（RI）小于1。这与氯喹形成鲜明对比，表明该系列的进一步发展将为我们提供针对CQR菌株的更有效的抗疟药。

  DOI：

  10.3390/molecules22030343
• 作为产物：
  描述：

  5-氟苯并[b]噻吩 、 1,1-二氯甲醚 在 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 反应 25.0h， 以81%的产率得到5-fluoro-1-benzothiophene-3-carbaldehyde
  参考文献：
  名称：

  Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

  摘要：

  The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 mu M and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 mu M). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 +/- 0.37 mu M). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b01374

文献信息

• NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS
  申请人：Oncostellae, S.L.

  公开号：EP3480201A1

  公开（公告）日：2019-05-08

  The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

  本发明涉及一种新型的二氢吡啶衍生物，其化学式为(I)：作为选择的核受体调节剂，所述核受体包括雄激素受体和糖皮质激素受体，以及其制备方法，包括所述化合物的制药组合物和利用所述化合物制造用于治疗可以通过调节雄激素受体和/或糖皮质激素受体改善的病理情况或疾病的药物，所述病理情况或疾病包括癌症、转移性癌症、良性前列腺增生、多囊卵巢综合征（PCOS）、脱发、多毛症、痤疮、性腺功能减退、肌肉消耗性疾病、虚弱、库欣综合征、抗精神病药物诱导的体重增加、肥胖、创伤后应激障碍和酗酒。
• [EN] NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS<br/>[FR] PYRAZOLO[3,4-D]PYRIMIDINES INHIBANT LES INFECTIONS PAR H. PYLORI
  申请人：ASTRAZENECA AB

  公开号：WO2003002567A1

  公开（公告）日：2003-01-09

  Compounds having the general formula , and pharmaceutical compositions containing them, and their use in the treatment or prophylaxis of H. pylori infection.

  具有一般式的化合物，以及含有它们的制药组合物，以及它们在治疗或预防H. pylori感染中的用途。
• Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections
  申请人：——

  公开号：US20040254183A1

  公开（公告）日：2004-12-16

  Compounds having the general formula 1 and pharmaceutical compositions containing them, and their use in the treatment or prophylaxis of H. pylori infection.

  具有通式1的化合物以及含有它们的药物组合物，以及它们在治疗或预防H. pylori感染中的应用。
• Study on the A3-coupling reaction catalyzed by readily available copper-containing minerals. Synthesis of propargylamines
  作者：Mátyás Milen、Gábor Györke、András Dancsó、Balázs Volk

  DOI：10.1016/j.tetlet.2019.151544

  日期：2020.3

  The highly atom efficient three-component reaction of aldehydes, secondary amines and acetylenes to form propargylamines (A(3)-coupling) has been studied with twelve readily available copper-containing minerals. It was found that the reaction could easily be performed in the presence of malachite, brochantite, chrysocolla and azurite in toluene at reflux. The desired products were obtained in good to excellent yields. (C) 2019 Elsevier Ltd. All rights reserved.
• NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS
  申请人：AstraZeneca AB

  公开号：EP1412355A1

  公开（公告）日：2004-04-28